The Sativex Patient Program is facilitated by PharmaPrograms on behalf of Chiesi Australia to enable the streamlined dispensing of Sativex through community pharmacies. Sativex, a TGA approved nabiximol product, is indicated for severe spasticity due to multiple sclerosis (MS). The Sativex Patient Program ensures price consistency and patient accessibility of the product Australia wide.